Zipalertinib Trial Meets Primary Endpoint in Lung Cancer Study
A clinical trial evaluating zipalertinib has successfully met its primary endpoint in a non-small cell lung cancer study.
PA
Priya Anand · Equities & Earnings Desk · 16 Aug 2026 · 1 min read
A clinical evaluation of zipalertinib has successfully met its primary endpoint in a study targeting lung cancer.
Further details regarding the specific trial data, patient cohorts, and subsequent regulatory filings have not yet been disclosed.
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →